Predicting Esophagitis After Chemoradiation Therapy for Non-Small Cell Lung Cancer: An Individual Patient Data Meta-Analysis
David A. Palma(Western University), George Rodrigues(London Health Sciences Centre), Sara Ramella(Università Campus Bio-Medico), Marta Moreno(Clinica Universidad de Navarra), R. Bryan Barriger(Indiana University – Purdue University Indianapolis), Kim De Ruyck(Ghent University), Cary Oberije(Maastricht University Medical Centre), Sarah Everitt(Peter MacCallum Cancer Centre), J. Belderbos(Netherlands Comprehensive Cancer Organisation), Suresh Senan(Amsterdam UMC Location VUmc), Lawrence B. Marks(University of North Carolina at Chapel Hill), Tae Hyun Kim(Ulsan College), Jeffrey D. Bradley(Hospital of the University of Pennsylvania), Andrew Warner(London Health Sciences Centre), Ramesh Rengan(University of Pennsylvania)
International Journal of Radiation Oncology*Biology*Physics
September 10, 2013
Cited by 190
Related Papers
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial
|The Lancet|2019|1.9k
Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non–Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study
|Journal of Clinical Oncology|2019|1.3k
Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial
|Journal of Clinical Oncology|2020|1.2k
Prophylactic Cranial Irradiation in Extensive Small-Cell Lung Cancer
|New England Journal of Medicine|2007|1.1k